NCT06583837 2026-02-27
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Fudan University
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT03755804 2026-02-23
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT04054167 2025-12-23
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03398161 2025-11-03
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05929716 2023-11-13
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01410344 2022-12-08
BMT CTN 0903
Medical College of Wisconsin
Phase 2 Completed
NCT00377195 2018-02-28
Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma
Trans Tasman Radiation Oncology Group
Phase 2 Unknown
NCT00088881 2017-05-25
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00193973 2017-02-17
Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma
Trans Tasman Radiation Oncology Group
Phase 2 Completed
NCT00578903 2016-04-22
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
Baylor College of Medicine
Phase 2 Terminated